In this work we have engineered a panel of BiTE-like albumin fusions with extended circulatory half-life programmed by the FcRn affinity of the albumin sequence that exhibit improved anti-tumour effects in a beyond state-of-the-art animal model. Here, FCGRT is linked to neoplasm.